| Date Filed | Type | Description |
| 02/14/2023 |
SC 13G/A
| Rock Springs Capital Management LP reports a 0% stake in Sierra Oncology, Inc. |
| 02/14/2023 |
SC 13G/A
| Rock Springs Capital Management LP reports a 0% stake in PhaseBio Pharmaceuticals, Inc. |
| 02/14/2023 |
SC 13G/A
| Rock Springs Capital Management LP reports a 4.9% stake in Mirum Pharmaceuticals, Inc. |
| 02/14/2023 |
SC 13G/A
| Rock Springs Capital Management LP reports a 4.2% stake in Compass Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| Rock Springs Capital Management LP reports a 7.8% stake in Tempest Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| Rock Springs Capital Management LP reports a 6.9% stake in Spruce Biosciences, Inc. |
| 02/14/2023 |
SC 13G/A
| Rock Springs Capital Management LP reports a 5.3% stake in MEREO BIOPHARMA GROUP PLC |
| 02/14/2023 |
SC 13G/A
| Rock Springs Capital Management LP reports a 7.6% stake in Inozyme Pharma, Inc. |
| 02/14/2023 |
SC 13G/A
| Rock Springs Capital Management LP reports a 7.3% stake in Immunocore Holdings plc |
| 02/14/2023 |
SC 13G
| Rock Springs Capital Management LP reports a 5.6% stake in AEGLEA BIOTHERAPEUTICS, INC. |
| 02/14/2023 |
SC 13G
| Rock Springs Capital Management LP reports a 5.4% stake in AGIOS PHARMACEUTICALS, INC. |
| 02/14/2023 |
SC 13G/A
| Rock Springs Capital Management LP reports a 5.9% stake in Aclaris Therapeutics, Inc. |
| 04/25/2022 |
SC 13G
| Rock Springs Capital Management LP reports a 6.1% stake in Inozyme Pharma, Inc. |
| 02/15/2022 |
SC 13G
| Rock Springs Capital Management LP reports a 5.1% stake in MEREO BIOPHARMA GROUP PLC |
| 02/14/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2022 |
SC 13G/A
| Rock Springs Capital Management LP reports a 6.9% stake in Spruce Biosciences, Inc. |
| 02/14/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2022 |
SC 13G/A
| Rock Springs Capital Management LP reports a 5% stake in Mirum Pharmaceuticals, Inc. |
| 02/14/2022 |
SC 13G/A
| Rock Springs Capital Management LP reports a 5.6% stake in Immunocore Holdings plc |
| 02/14/2022 |
SC 13G/A
| Rock Springs Capital Management LP reports a 5.4% stake in Compass Therapeutics, Inc. |
| 02/14/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/03/2022 |
SC 13G
| Rock Springs Capital Management LP reports a 11.5% stake in Tempest Therapeutics, Inc. |
| 12/30/2021 |
SC 13G
| Rock Springs Capital Management LP reports a 5.4% stake in Compass Therapeutics, Inc. |
| 07/15/2021 |
SC 13G/A
| Rock Springs Capital Management LP reports a 4.7% stake in Tempest Therapeutics, Inc. |
| 07/08/2021 |
SC 13G
| Rock Springs Capital Management LP reports a 9.7% stake in Tempest Therapeutics, Inc. |
| 06/24/2021 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 05/17/2021 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 04/19/2021 |
SC 13G
| Rock Springs Capital Management LP reports a 5.3% stake in Immunocore Holdings plc |
| 03/01/2021 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
|